Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
NCT05796453 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.
Conditions Studied
Interventions
- DEVICE Clareon Vivity IOL - Non Toric
- DEVICE Clareon Vivity IOL - Toric
- DEVICE Clareon PanOptix Trifocal IOL - Non Toric
- DEVICE Clareon PanOptix Trifocal IOL - Toric
Study Locations (7)
California
- Wolstan & Goldberg Eye Associates — Torrance
Florida
- Levenson Eye Associates — Jacksonville
New York
- Eye Surgeons of CNY — Liverpool
Oklahoma
- Tulsa Ophthalmology — Tulsa
Texas
- Chu Eye Institute — Fort Worth
Utah
- The Eye Institute of Utah — Salt Lake City
Other
- Centro Oftalmologico Metropolitano — San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2023-09-19 |
| Est. Completion | 2028-06 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05796453
The ClinicalTrials.gov registry entry for NCT05796453 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 111 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Presbyopia appearing as the primary indexed condition, and to 4 interventions — of which Clareon Vivity IOL - Non Toric is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05796453 reports 7 study locations spanning 7 distinct geographic areas — top geographies include California, Florida, New York. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05796453 about?
NCT05796453 is a clinical study titled "Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix". The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.
What is the current status of trial NCT05796453?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 470 participants. The study started on 2023-09-19. Estimated completion is 2028-06.
What conditions does trial NCT05796453 study?
This clinical trial studies the following conditions: Presbyopia, Astigmatism, Aphakia. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05796453?
The interventions under investigation include: Clareon Vivity IOL - Non Toric (DEVICE), Clareon Vivity IOL - Toric (DEVICE), Clareon PanOptix Trifocal IOL - Non Toric (DEVICE), Clareon PanOptix Trifocal IOL - Toric (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05796453?
This trial is sponsored by Alcon Research, which has 111 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05796453 being conducted?
This trial has 7 study locations across California, Florida, New York, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.